Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/26/2026 | $12.00 | Buy | H.C. Wainwright |
| 11/6/2024 | Buy → Neutral | H.C. Wainwright | |
| 11/5/2024 | Outperform → Sector Perform | RBC Capital Mkts | |
| 7/25/2023 | $10.00 | Hold → Buy | Needham |
| 3/22/2023 | $10.00 | Buy | Jefferies |
| 2/13/2023 | $4.00 → $11.00 | Sector Perform → Outperform | RBC Capital Mkts |
| 5/25/2022 | $16.00 → $4.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 3/10/2022 | $20.00 | Buy | Brookline Capital |
S-8 - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
10-Q - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
8-K - Verrica Pharmaceuticals Inc. (0001660334) (Filer)
WEST CHESTER, Pa., May 28, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the Jefferies Global Healthcare Conference. Jefferies Global Healthcare Conference, June 2-4, 2026Event details:Date: Thursday, June 4, 2026Time: 11:05am ETLocation: New York Participants may access a live webcast of the event by clicking the link here. The webcast can also be accessed in the Investors/Presentations & Eve
WEST CHESTER, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that Jayson Rieger, PhD, MBA, President and Chief Executive Officer of Verrica Pharmaceuticals, will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ. H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ, May 19, 2026Event details:Date: Tuesday, May 19, 2026Time: 1:30pm ETLocation: NASDAQ Participants may access a live webcast of the event by clicking the link here. The webcast can a
– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator units since launch – – Company announces achievement of over 50% of current targeted enrollment in the first trial in global Phase 3 common warts program and expects to initiate the second trial in the US and Japan in mid-2026 – – Company reports total revenue of $5.0 million in Q1 2026, including U.S. YCANTH net product revenue of $4.3 million in Q1 2026, up 16.2% over previous quarter and 25.4% year-over-year – – YCANTH commercial launch in Japan by partner Torii Pharmaceu
H.C. Wainwright resumed coverage of Verrica Pharmaceuticals with a rating of Buy and set a new price target of $12.00
H.C. Wainwright downgraded Verrica Pharmaceuticals from Buy to Neutral
RBC Capital Mkts downgraded Verrica Pharmaceuticals from Outperform to Sector Perform
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
3/A - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
3 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
4 - Verrica Pharmaceuticals Inc. (0001660334) (Issuer)
Submission status for VERRICA PHARMACEUTICALS INC's drug YCANTH (ORIG-1) with active ingredient CANTHARIDIN has changed to 'Approval' on 07/21/2023. Application Category: NDA, Application Number: 212905, Application Classification: Type 5 - New Formulation or New Manufacturer
– Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue of $1.9 million, including a provision for product returns of $1.7 million– – Company expects existing distributor inventory to support most demand for dispensed applicator units into the first quarter of 2025 – – Company continues to look for ways to manage expenses and expand access to YCANTH® for the treatment of molluscum contagiosum – – Company announces new senior leadership with appointments of Dr. Jayson Rieger as Chief Executive Officer and John Kirby as Interim Chi
WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced financial results for the second quarter ended June 30, 2021. "This quarter, we continued to ramp up commercial preparations for the potential FDA approval of VP-102, our lead product candidate for the treatment of molluscum contagiosum, including strengthening our senior leadership team and ensuring patient access to VP-102 through productive dialogue with medical providers and payors," said Ted White, Verrica's President and Chief Executive Officer. "With a
Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica") (NASDAQ:VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the appointment of Terry Kohler as Chief Financial Officer. Mr. Kohler is a strategic and operational finance leader with over 20 years of commercial business experience, most recently at a global pharmaceutical company with annual revenues over $2 billion. Mr. Kohler is replacing Brian Davis, who is leaving Verrica to pursue other opportunities. "Te
SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13D/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
SC 13G/A - Verrica Pharmaceuticals Inc. (0001660334) (Subject)
– Company reports record demand for YCANTH® as dispensed applicator units grew to 15,302 in Q1 2026, up 12.1% over the previous quarter and 51.3% year-over-year, and has now exceeded 100,000 dispensed applicator units since launch – – Company announces achievement of over 50% of current targeted enrollment in the first trial in global Phase 3 common warts program and expects to initiate the second trial in the US and Japan in mid-2026 – – Company reports total revenue of $5.0 million in Q1 2026, including U.S. YCANTH net product revenue of $4.3 million in Q1 2026, up 16.2% over previous quarter and 25.4% year-over-year – – YCANTH commercial launch in Japan by partner Torii Pharmaceu
WEST CHESTER, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological diseases, including skin cancers, today announced that it will host a conference call and live webcast at 4:30 p.m. ET on Tuesday, May 12, 2026, to discuss the Company's financial results for the first quarter ending March 31, 2026, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-833-316-2483 (domestic) or 1-785-838-9284 (international) and using the conference ID: VERRICA. Participants are asked to dial in 10
WEST CHESTER, Pa., March 05, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or "the Company") (NASDAQ:VRCA), a dermatology therapeutics company developing and selling medications for skin diseases requiring medical interventions, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Wednesday, March 11, 2026, to discuss the Company's financial results for the fourth quarter and full year ending December 31, 2025, and provide a corporate update. Individuals may participate in the live call via telephone by dialing 1-800-343-4136 (domestic) or 1-203-518-9843 (international) and using the conference ID: VERRICA. Participants are asked to di